Functional impact of colorectal cancer-associated mutations in the transcription factor E2F4

Paquin,Marie-Christine; Leblanc,Caroline; Lemieux,Etienne; Bian,Benjamin; Rivard,Nathalie

doi:10.3892/ijo.2013.2131

Functional impact of colorectal cancer-associated mutations in the transcription factor E2F4

Authors:
- Marie-Christine Paquin
- Caroline Leblanc
- Etienne Lemieux
- Benjamin Bian
- Nathalie Rivard
View Affiliations

Affiliations: Department of Anatomy and Cellular Biology, Cancer Research Pavillon, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec J1E4K8, Canada
Published online on: October 8, 2013 https://doi.org/10.3892/ijo.2013.2131
Pages: 2015-2022
Copyright: © Paquin et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The transcription factor E2F4 plays a critical role in cell cycle progression of normal and cancerous intestinal epithelial cells. Contrary to other E2Fs, the coding region of the E2F4 gene contains a longer spacer segment of a CAG trinucleotide repeat sequence encoding 13 consecutive serine residues, which is highly vulnerable to frameshift mutations in situations of genetic instability. Mutations in this region of the E2F4 gene have been observed in colorectal tumors with microsatellite instability. However, the effect of these changes on its function in colorectal cancer cells is currently unknown. We generated E2F4(CAG)12 and E2F4(CAG)14 mutants and compared their activity to the E2F4 wild-type, E2F4(CAG)13. Luciferase assays with the thymidine kinase-luc reporter gene revealed that the mutants were more transcriptionally active than wild-type E2F4. The mechanism of increased activity of E2F4 was primarily related to protein stability, due to a significantly enhanced half-life of E2F4 mutants comparatively to that of wild-type E2F4. However, the association with the pocket protein p130/RBL2 did not account for this increased protein stability. Sequencing analysis of the endogenous E2F4 gene in a series of colorectal cancer cell lines showed that the microsatellite-unstable cell line SW48 exhibited a serine deletion in this gene. Accordingly, E2F4 half-life was much more elevated in SW48 cells in comparison to Caco-2/15, a microsatellite-stable cell line. Notably, in soft-agar assays, both mutants more potently increased anchorage-independent growth in comparison to wild-type E2F4. In conclusion, our data demonstrate that cancer-associated E2F4 mutations enhance the capacity of colorectal cancer cells to grow without anchorage, thereby contributing to tumor progression.

View Figures

View References

1.	Yang VW, Lewis J, Wang TC and Rustgi AK: Colon cancer: an update and future directions. Gastroenterology. 138:2027–2028. 2010. View Article : Google Scholar : PubMed/NCBI
2.	van der Flier LG and Clevers H: Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol. 71:241–260. 2009.
3.	Worthley DL and Leggett BA: Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev. 31:31–38. 2010.PubMed/NCBI
4.	Boland CR and Goel A: Microsatellite instability in colorectal cancer. Gastroenterology. 138:2073–2087.e3. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Tsantoulis PK and Gorgoulis VG: Involvement of E2F transcription factor family in cancer. Eur J Cancer. 41:2403–2414. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Chen HZ, Tsai SY and Leone G: Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer. 9:785–797. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Gaubatz S, Lindeman GJ, Ishida S, Jakoi L, Nevins JR, Livingston DM and Rempel RE: E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. Mol Cell. 6:729–735. 2000. View Article : Google Scholar : PubMed/NCBI
8.	Garneau H, Paquin MC, Carrier JC and Rivard N: E2F4 expression is required for cell cycle progression of normal intestinal crypt cells and colorectal cancer cells. J Cell Physiol. 221:350–358. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Deschenes C, Alvarez L, Lizotte ME, Vezina A and Rivard N: The nucleocytoplasmic shuttling of E2F4 is involved in the regulation of human intestinal epithelial cell proliferation and differentiation. J Cell Physiol. 199:262–273. 2004. View Article : Google Scholar : PubMed/NCBI
10.	Yoshitaka T, Matsubara N, Ikeda M, Tanino M, Hanafusa H, Tanaka N and Shimizu K: Mutations of E2F-4 trinucleotide repeats in colorectal cancer with microsatellite instability. Biochem Biophys Res Commun. 227:553–557. 1996. View Article : Google Scholar : PubMed/NCBI
11.	Souza RF, Yin J, Smolinski KN, et al: Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Cancer Res. 57:2350–2353. 1997.PubMed/NCBI
12.	Ikeda M, Orimo H, Moriyama H, et al: Close correlation between mutations of E2F4 and hMSH3 genes in colorectal cancers with microsatellite instability. Cancer Res. 58:594–598. 1998.PubMed/NCBI
13.	Moriyama H, Sasamoto H, Kambara T, et al: E2F-4 mutation in hereditary non-polyposis colorectal cancer. J Exp Clin Cancer Res. 21:185–189. 2002.PubMed/NCBI
14.	Sardet C, Vidal M, Cobrinik D, Geng Y, Onufryk C, Chen A and Weinberg RA: E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle. Proc Natl Acad Sci USA. 92:2403–2407. 1995. View Article : Google Scholar : PubMed/NCBI
15.	Wu CL, Zukerberg LR, Ngwu C, Harlow E and Lees JA: In vivo association of E2F and DP family proteins. Mol Cell Biol. 15:2536–2546. 1995.PubMed/NCBI
16.	Perreault N and Beaulieu JF: Use of the dissociating enzyme thermolysin to generate viable human normal intestinal epithelial cell cultures. Exp Cell Res. 224:354–364. 1996. View Article : Google Scholar : PubMed/NCBI
17.	Dou QP, Zhao S, Levin AH, Wang J, Helin K and Pardee AB: G1/S-regulated E2F-containing protein complexes bind to the mouse thymidine kinase gene promoter. J Biol Chem. 269:1306–1313. 1994.PubMed/NCBI
18.	Jansen-Durr P, Meichle A, Steiner P, et al: Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci USA. 90:3685–3689. 1993. View Article : Google Scholar : PubMed/NCBI
19.	Oswald F, Lovec H, Moroy T and Lipp M: E2F-dependent regulation of human MYC: Trans-activation by cyclins D1 and A overrides tumour suppressor protein functions. Oncogene. 9:2029–2036. 1994.PubMed/NCBI
20.	Hateboer G, Kerkhoven RM, Shvarts A, Bernards R and Beijersbergen RL: Degradation of E2F by the ubiquitin-protea-some pathway: Regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev. 10:2960–2970. 1996. View Article : Google Scholar : PubMed/NCBI
21.	Hofmann F, Martelli F, Livingston DM and Wang Z: The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev. 10:2949–2959. 1996. View Article : Google Scholar : PubMed/NCBI
22.	Martelli F and Livingston DM: Regulation of endogenous E2F1 stability by the retinoblastoma family proteins. Proc Natl Acad Sci USA. 96:2858–2863. 1999. View Article : Google Scholar : PubMed/NCBI
23.	Heinen CD, Richardson D, White R and Groden J: Microsatellite instability in colorectal adenocarcinoma cell lines that have full-length adenomatous polyposis coli protein. Cancer Res. 55:4797–4799. 1995.PubMed/NCBI
24.	Boyer JC, Umar A, Risinger JI, et al: Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res. 55:6063–6070. 1995.PubMed/NCBI
25.	Takashima H, Matsumoto Y, Matsubara N, et al: Effect of naturally occurring E2F-4 alterations on transcriptional activation and proliferation in transfected cells. Lab Invest. 81:1565–1573. 2001. View Article : Google Scholar : PubMed/NCBI
26.	Martelli F, Hamilton T, Silver DP, et al: p19ARF targets certain E2F species for degradation. Proc Natl Acad Sci USA. 98:4455–4460. 2001. View Article : Google Scholar : PubMed/NCBI
27.	Vlach J, Hennecke S and Amati B: Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 16:5334–5344. 1997. View Article : Google Scholar : PubMed/NCBI
28.	Diehl JA, Cheng M, Roussel MF and Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12:3499–3511. 1998. View Article : Google Scholar : PubMed/NCBI
29.	Vandel L and Kouzarides T: Residues phosphorylated by TFIIH are required for E2F-1 degradation during S-phase. EMBO J. 18:4280–4291. 1999. View Article : Google Scholar : PubMed/NCBI
30.	Dunn EF, Iida M, Myers RA, et al: Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Oncogene. 30:561–574. 2011. View Article : Google Scholar : PubMed/NCBI
31.	Chen C and Wells AD: Comparative analysis of E2F family member oncogenic activity. PLoS One. 2:e9122007. View Article : Google Scholar : PubMed/NCBI
32.	Xu G, Livingston DM and Krek W: Multiple members of the E2F transcription factor family are the products of oncogenes. Proc Natl Acad Sci USA. 92:1357–1361. 1995. View Article : Google Scholar : PubMed/NCBI
33.	Rakha EA, Pinder SE, Paish EC, Robertson JF and Ellis IO: Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis. J Pathol. 203:754–761. 2004. View Article : Google Scholar : PubMed/NCBI
34.	Mori S, Chang JT, Andrechek ER, et al: Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene. 28:2796–2805. 2009. View Article : Google Scholar : PubMed/NCBI